Evidence map›Paper›PMID 42121215›Full record

ArticleNeurological research and practice2026

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol.

Felix Kohle, Franz Felix Konen, Ulrike Grittner, Daniel Schulze, Stefanie Glaubitz, Christopher Nelke, Christina B Schroeter, Niklas Huntemann, Peter Trillenberg, Julian Großkreutz and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Felix Kohle *Department of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-4429-0367
Franz Felix Konen *Department of Neurology, Hannover Medical School, Hannover, Germany.
Ulrike GrittnerInstitute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, corporate member of, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Daniel SchulzeInstitute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, corporate member of, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Stefanie GlaubitzDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Christopher NelkeDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Christina B SchroeterDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Niklas HuntemannDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Peter TrillenbergDepartment of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Julian GroßkreutzDepartment of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Benedikt SchoserDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Charlotte SchubertInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jana ZschüntzschDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Michael SchroeterDepartment of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany.
Tobias HegelmaierDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Jörn Peter SiebDepartment of Neurology, Helios Hanseklinikum Stralsund, Stralsund, Germany.
Tobias RuckDepartment of Neurology with, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Bochum, Germany.
Sven MeuthDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Heinz WiendlDepartment of Neurology and Neurophysiology, University Hospital Freiburg, Freiburg, Germany.
Christian Wolfgang KellerDepartment of Neurology and Neurophysiology, University Hospital Freiburg, Freiburg, Germany.
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Sophie LehnererDepartment of Neurology with Experimental Neurology, Neuroscience Clinical Resarch Center, Charite Universitatsmedizin Berlin, Berlin, Germany.
Andreas Meisel *Department of Neurology with Experimental Neurology, Neuroscience Clinical Resarch Center, Charite Universitatsmedizin Berlin, Berlin, Germany.
Frauke Stascheit *Department of Neurology with Experimental Neurology, Neuroscience Clinical Resarch Center, Charite Universitatsmedizin Berlin, Berlin, Germany. frauke.stascheit@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyasthenia gravis has a variable disease course. Early identification of patients with a highly active disease is crucial to prevent myasthenic exacerbations and crisis, necessitating more aggressive immunotherapy. However, no biomarkers currently exist to identify patients at risk for highly active disease course.

objectiveThe PROGNO-MG study aims to identify blood-based biomarker signatures associated with a highly active disease course in immunotherapy-naïve patients with acetylcholine-receptor-antibody positive (AChR

methodsThis is an investigator-initiated prospective, multicentric, observational study. Seventy newly diagnosed immunotherapy-naïve AChR PERSPECTIVE: The results will provide evidence for prognostic biomarkers, supporting risk stratification and early individualized treatment for AChR

trial registrationThe study is registered in the German clinical trial register (DRKS00035457).

Indexed as

Acetylcholine receptor antibodiesComplement activationDisease activityGeneralized myasthenia gravisImmune cell phenotypingMyasthenia gravisPrognostic biomarkersProteomicsRisk stratification

Identifiers

PMID42121215
PMCPMC13169798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.